Obesity drug competition expected to intensify by 2030
Viking Therapeutics’ dual GLP-1/GIP receptor agonist VK2735 could become a direct competitor to Eli Lilly’s Mounjaro/Zepbound (tirzepatide), predicts data analytics company GlobalData.
In February 2024, Viking Therapeutics published Phase IIa results for its VK2735 candidate, which is being investigated both as a weekly subcutaneous injection and as an oral tablet to treat obesity.
The results showed that after 13 weeks of once-weekly subcutaneous injections of VK2735, patients experienced average weight losses of 9.2kg, 10.7kg, 13.3kg, 14.6kg, and 1.8kg in the 2.5mg, 5mg, 10mg, 15mg, and placebo groups, respectively.
This translates to a placebo-adjusted weight loss from baseline of 7.4%, 9.2%, 11.3%, and 13.10% in the treatment groups.
In a Phase I trial of an oral tablet formulation of VK2735, up to 3.3% placebo-adjusted mean weight loss (5.3% from baseline) was observed after 28 days.
The company plans to initiate a Phase II trial with the oral formulation of VK2735 in obesity later this year.
Costanza Alciati, Pharma Analyst at GlobalData, commented: “Competition in the obesity field is expected to intensify toward the end of this decade, as many companies have treatments in development expected to launch in the late 2020s. The promising results could give VK2735 a competitive edge over other candidates in the pipeline. Assuming VK2735 enters Phase III clinical trials next year, it could become one of the next therapies to enter the market, directly competing with Eli Lilly’s tirzepatide due to its similar mechanism of action.”
However, GlobalData cautions, pipeline candidates entering the market will also have to compete against Wegovy, which has just been approved in the UK and the EU as the first drug to reduce the risk of cardiovascular events in adults with obesity.
Diana Spencer, Senior Digital Content Editor, DDW
